Dorzolamide

• UNSPSC Description:

  Dorzolamide (L671152) is a potent carbonic anhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity[1].

• Target Antigen:

  Carbonic Anhydrase

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Dorzolamide.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=S(C(S1)=CC2=C1S([C@@H](C)C[C@@H]2NCC)(=O)=O)(N)=O

• Molecular Weight:

  324.44

• References & Citations:

  [1]J Biollaz, et al. Whole-blood pharmacokinetics and metabolic effects of the topical carbonic anhydrase inhibitor dorzolamide. Eur J Clin Pharmacol. 1995;47(5):455-60.|[2]Sangly P Srinivas, et al. Inhibition of carbonic anhydrase activity in cultured bovine corneal endothelial cells by dorzolamide. Invest Ophthalmol Vis Sci. 2002 Oct;43(10):3273-8.|[3]Belal M Ali, et al. Dorzolamide synergizes the antitumor activity of mitomycin C against Ehrlich's carcinoma grown in mice: role of thioredoxin-interacting protein. Naunyn Schmiedebergs Arch Pharmacol. 2015 Dec;388(12):1271-82.Anal Chem. 2020 Dec 15;92(24):15745-15756.|ETH Zurich. 2020 Dec.|J Pharmaceut Biomed. 2020, 113870.|Cell Rep. 2024 Nov 27;43(12):114996.|Sci Data. 2024 Sep 19.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Launched

• CAS Number:

  120279-96-1